ScripPublic biopharmaceutical company fundraising activity in late June and early July was somewhat remarkable after the BIO International Convention in early June, during which drug developers and investo
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear
ScripWho: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C
ScripKymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa